You are here

Vyndaqel

Pfizer escapes proposed class action lawsuit over patient copay assistance

Pfizer escapes proposed class action lawsuit over patient copay assistance

Fierce Pharma

copay asssistance programs

Flag link:

U.S. Supreme Court rebuffs Pfizer plan to help patients pay for heart medication

U.S. Supreme Court rebuffs Pfizer plan to help patients pay for heart medication

Reuters

Flag link:

Pfizer musters J&J, PhRMA's support in closely watched Vyndaqel copay assistance case at Supreme Court

Pfizer musters J&J, PhRMA's support in closely watched Vyndaqel copay assistance case at Supreme Court

Fierce Pharma

copay asssistance programs

Flag link:

Pfizer takes Vyndaqel copay fight to Supreme Court, decrying 'staggeringly overbroad' anti-kickback rule

Pfizer takes Vyndaqel copay fight to Supreme Court, decrying 'staggeringly overbroad' anti-kickback rule

Fierce Pharma

Flag link:

Pfizer loses court battle to keep its Vyndaqel copay assistance for Medicare patients—again

Pfizer loses court battle to keep its Vyndaqel copay assistance for Medicare patients—again

Fierce Pharma

copay asssistance programs

Flag link:

Bridgebio sets its heart on besting Pfizer

Bridgebio sets its heart on besting Pfizer

EP Vantage

transthyretin amyloid cardiomyopathy

Flag link:

Pfizer prohibited from subsidizing its heart drugs for Medicare patients

Pfizer prohibited from subsidizing its heart drugs for Medicare patients

Beckers Hospital Review

Flag link:

Pfizer victory in Vyndaqel copay lawsuit could kneecap the government's only control on prices, lawyer warns

Pfizer victory in Vyndaqel copay lawsuit could kneecap the government's only control on prices, lawyer warns

Fierce Pharma

Flag link:

Pfizer sues for U.S. permission to assist patients needing expensive heart drugs

Pfizer sues for U.S. permission to assist patients needing expensive heart drugs

Reuters

federal government

Flag link:

Pfizer's blockbuster-to-be Vyndaqel is too costly for heart patients, study suggests

Pfizer's blockbuster-to-be Vyndaqel is too costly for heart patients, study suggests

Fierce Pharma

Flag link:

Pfizer Gains European Approval for Amyloidosis Drug Vyndaqel

Pfizer Gains European Approval for Amyloidosis Drug Vyndaqel

Fierce Biotech

transthyretin amyloidosis

Flag link:

Pfizer's heart med Vyndaqel off and running thanks to diagnosis push: execs

Pfizer's heart med Vyndaqel off and running thanks to diagnosis push: execs

Fierce Pharma

Flag link:

Watch Out, Pfizer: This $2 Billion Biotech Is Coming for You

Watch Out, Pfizer: This $2 Billion Biotech Is Coming for You

Motley Fool

Eidos Therapeutics

Flag link:

These Biotechs Were Focused on One Line on Pfizer’s Earnings Report

These Biotechs Were Focused on One Line on Pfizer’s Earnings Report

Motley Fool

Akcea Therapeutics

Ionis Pharmaceuticals

Eidos Therapeutics

Flag link:

Pfizer's heart drug impresses with fast US launch

Pfizer's heart drug impresses with fast US launch

Biopharma Dive

Flag link:

Pfizer's Vyndaqel franchise, buoyed by diagnoses, is poised for 'a decisive beat': analyst

Pfizer's Vyndaqel franchise, buoyed by diagnoses, is poised for 'a decisive beat': analyst

Fierce Pharma

ATTR amyloidosis

Flag link:

5 Biggest New Drugs Approved in 2019 So Far

5 Biggest New Drugs Approved in 2019 So Far

Motley Fool

multiple sclerosis

metastatic bladder cancer

Flag link:

Pfizer's new Vyndaqel franchise worth far more than $1.5B, analyst figures

Pfizer's new Vyndaqel franchise worth far more than $1.5B, analyst figures

Fierce Pharma

Flag link:

FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea

FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea

Xconomy

Flag link:

6 Things Alnylam Investors Need to Know About Pfizer's Next Blockbuster Drug

6 Things Alnylam Investors Need to Know About Pfizer's Next Blockbuster Drug

Motley Fool

ATTR amyloidosis

Flag link:

Pages